This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
Dermatology and Therapy Open Access 25 November 2021
-
Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis
Scientific Reports Open Access 11 September 2017
-
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
Dermatology and Therapy Open Access 29 December 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratner, M. IL-17–targeting biologics aim to become standard of care in psoriasis. Nat Biotechnol 33, 3–4 (2015). https://doi.org/10.1038/nbt0115-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0115-3
This article is cited by
-
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
Dermatology and Therapy (2022)
-
First eczema biologic debuts but price could restrict use
Nature Biotechnology (2017)
-
Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis
Scientific Reports (2017)
-
New anti-IL-23 drugs raise hopes for psoriasis plaque clearance
Nature Biotechnology (2016)
-
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
Dermatology and Therapy (2016)